abrdn plc Increases Stock Position in BioNTech SE (NASDAQ:BNTX)

abrdn plc increased its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 70.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 385,668 shares of the company's stock after acquiring an additional 159,676 shares during the quarter. abrdn plc owned about 0.16% of BioNTech worth $43,947,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Planning Capital Management Corp boosted its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. increased its holdings in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after purchasing an additional 388 shares during the period. GAMMA Investing LLC grew its position in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after buying an additional 111 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of BioNTech in the third quarter valued at about $210,000. Finally, Probity Advisors Inc. acquired a new stake in shares of BioNTech in the third quarter valued at about $216,000. 15.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and upped their target price for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. BMO Capital Markets reaffirmed an "outperform" rating on shares of BioNTech in a research note on Monday, December 2nd. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating for the company in a research note on Tuesday, November 26th. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $150.00 price objective on shares of BioNTech in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $142.72.

BioNTech Price Performance

Shares of BNTX stock traded down $2.33 during trading on Friday, hitting $117.61. The company's stock had a trading volume of 416,114 shares, compared to its average volume of 687,867. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The business has a fifty day moving average of $117.30 and a 200-day moving average of $108.36. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.